The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL).
Michael Wang
Consultant or Advisory Role - Janssen Research & Development
Honoraria - Janssen Research & Development
Research Funding - Janssen Research & Development; Pharmacyclics
Leo I. Gordon
No relevant relationships to disclose
Simon Rule
Consultant or Advisory Role - NAPP Pharmaceuticals; Pharmacyclics; Roche
Andre Goy
Consultant or Advisory Role - Johnson & Johnson; Pharmacyclics
Research Funding - Johnson & Johnson; Pharmacyclics
Olivier Hermine
Honoraria - Johnson & Johnson
Aleksandra Rizo
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Sen Hong Zhuang
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Martin H. Dreyling
Consultant or Advisory Role - Janssen Research & Development; Roche
Honoraria - Janssen Research & Development; Mundipharma; Roche
Research Funding - Janssen Research & Development; Mundipharma; Roche